EUVIMEDEUVIMED entdecken
Crossref

Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma

Zhuowei Yao, Jingshuo Wang, Yongquan Jiang, Yi Zhang, Jun Liu, Li Dai, Silin Shen, Xiang Zhou, Qiang Liu, Luying Zheng, Minfei Qian, Jiping Li iD

Head & Neck · 2025

DOI: 10.1002/hed.27915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Zhuowei Yao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Cetuximab, Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Shanghai Shenkang Hospital Development Center, Shanghai Municipal Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Head and neck cancer cells commonly express programmed death ligand 1 (PD‐L1) and epidermal growth factor receptor (EGFR), both of which play pivotal roles in the antitumor cellular immune response. Pembrolizumab, a PD‐1 inhibitor, and cetuximab, an EGFR inhibitor, are typically effective agents combined with neoadjuvant platinum‐based chemotherapy for the treatment of head and neck squamous cell carcinoma (HNSCC). This study aims to evaluate the efficacy and safety of neoadjuvant immunochemotherapy in patients with HNSCC.

Methods

Patients with HNSCC underwent radical surgery and complete cervical lymph node dissection following neoadjuvant immunochemotherapy at RenJi Hospital from January 2021 to June 2024 were retrospectively analyzed. The primary endpoint was major pathological response (MPR). We further explored the relationship between the efficacy and immune estimators.

Findings

Twenty‐one patients were enrolled in this retrospective study. The MPR was 66.7%, including 11 patients who achieved a pathological complete response (pCR). The overall response rate (ORR) was 90.5%, and the complete response (CR) rate was 28.6%. The oropharynx, as the primary site, was the sensitive tumor type to neoadjuvant immunochemotherapy. The most common adverse event (AEs) was anemia (61.9%). No grade 4 AE or delayed surgery was reported. Laryngeal preservation rates were 90.9% (10/11), and pathological findings confirmed negative surgical margins for all patients. Moreover, pre‐treatment peripheral lymphocyte count, monocyte count, and platelet to lymphocyte ratio (PLR) displayed a significant correlation with the treatment response.

Conclusion

Pembrolizumab plus cetuximab with chemotherapy for patients with HNSCC is a feasible and safe clinical protocol fulfilling organ preservation and life quality improvement. Pre‐treatment peripheral immune estimators could help to screen patients who may respond to the neoadjuvant immunochemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CetuximabAntibodies, Monoclonal, HumanizedNeoadjuvant TherapySquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdult

Stichwörter der Autor:innen

efficacyhead and neck squamous cell carcinomaimmune marker analysismajor pathological responseneoadjuvant immunochemotherapy

Substanzen

CetuximabAntibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Department of Otolaryngology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

ORCID-Profile: Jiping Li

Förderung

  • Shanghai Shenkang Hospital Development Center
  • Shanghai Municipal Hospital Development Center

Zitieren

APA

Yao, Z., Wang, J., Jiang, Y., Zhang, Y., Liu, J., Dai, L., Shen, S., Zhou, X., Liu, Q., Zheng, L., Qian, M., & Li, J. (2025). Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Head & Neck. https://doi.org/10.1002/hed.27915

Vancouver

Yao Z, Wang J, Jiang Y, Zhang Y, Liu J, Dai L, et al. Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Head & Neck. 2025. doi:10.1002/hed.27915

BibTeX
@article{Yao2025,
  author = {Yao, Zhuowei and Wang, Jingshuo and Jiang, Yongquan and Zhang, Yi and Liu, Jun and Dai, Li and Shen, Silin and Zhou, Xiang and Liu, Qiang and Zheng, Luying and Qian, Minfei and Li, Jiping},
  title = {Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.27915}
}
Kostenlos starten →